Federal Agency Support

Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)

The JPEO-CBRND is a component of the U.S. Department of Defense’s Chemical and Biological Program. The JPEO-CBRND leads, manages and supports the country’s investments in chemical, biological, radiological, and nuclear (CBRN) defense equipment and medical countermeasures (MCMs). This includes development activities, acquisition, fielding and life cycle support. In 2023, Humanetics entered into an Other Transaction Authority (OTA) Contract with JPEO-CBRND to develop BIO 300 as a MCM to prevent bodily harm caused by acute exposure to radiation. For more information about JPEO-CBRND, click here.

Armed Forces Radiobiology Research Institute (AFRRI) 

Humanetics entered into a Master Cooperative Research and Development Agreement (CRADA) with the Uniformed Services University of the Health Sciences (USU) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). The Congressionally-chartered USU is a fully-accredited graduate-education university operated by the Department of Defense (DoD) and is located in Bethesda, Maryland. HJF, located in Rockville, Maryland, is a private, not-for-profit organization chartered by Congress to support medical education and research at USU and throughout the military medical community.

Under the Master CRADA, Humanetics  collaborated with Dr. Michael Landauer (now retired) at AFRRI to test and validate the efficacy of BIO 300 as a medical radiation countermeasure.   Dr. Landauer is one of the original scientists to discover BIO 300's protective effects.  He is a world leader in radiation injury and development of models that can lead to safe and effective drugs for use by the military, first responders and civilians.

To learn more about the Armed Forces Radiobiology Research Institute (AFRRI), click here.

Congressionally Directed Medical Research Programs (CDRMP)

The Department of Defense’s CDMRP fosters novel approaches to biomedical research in response to the expressed needs of its stakeholders – the American public, the U.S. military, and U.S. Congress. The CDMRP fills research gaps by funding high impact, high risk and high reward projects that other agencies may not venture to fund. All of the programs managed by the CDMRP share the common goal of advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. Humanetics has been awarded several grants from the CDMRP in 2017, 2019, 2020 and 2022 to advance development of BIO 300 as a medical countermeasure for acute radiation exposure, radiation-induced lung injury and COVID-induced lung injury. For more information about CDMRP, click here.

National Cancer Institute (NCI)

It is the mission of NCI to address research and training needs for the cause, diagnosis and treatment of cancer. NCI has been a key funding source for Humanetics’ preclinical and clinical studies for BIO 300 in the areas of lung and prostate cancer.  NCI is intensely interested in developing both radioprotectants and radiosensitizers to improve the treatment of solid tumors.  Humanetics has been working with NCI under various grants and contracts since 2012.  To learn more about NCI, click here.

Biomedical Advanced Research and Development Authority (BARDA)

The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.  In 2011,  Humanetics received a significant contract from BARDA to collaboratively develop BIO 300 for protection of the pulmonary system resulting from exposure to radiation.  To learn more about BARDA, click here.

National Institute of Allergy and Infectious Diseases (NIAID)

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID is one of the 27 Institutes and Centers of the National Institutes of Health (NIH).  Humanetics was awarded a small business innovation research grant from NIAID in 2016 to further develop BIO 300 to protect lung function after exposure to radiation.  For more information about NIAID, click here.